Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

Diagnosis of solid tumor that overexpresses epidermal growth factor receptor (EGFR) including, but not limited to, the following:

Breast cancer
Lung cancer
Colon cancer
Pancreatic cancer
Head and neck cancer
Kidney cancer
Sarcoma

Advanced disease

Must have failed or become intolerant to prior standard therapy and is no longer likely to respond to such therapy
Measurable or nonmeasurable disease
ECOG performance status 0-1
ANC ≥ 1,500/mm³
Platelet count > 100,000/mm³
Hemoglobin > 9 g/dL
Bilirubin < 1.5 times upper limit of normal (ULN)
Alkaline phosphatase < 3.0 times ULN (5.0 times ULN if liver has tumor involvement)
Aspartate aminotransferase (AST) and alanine aminotransferase (*ALT) < 3.0 times upper limit of normal (ULN) (5.0 times ULN if liver has tumor involvement)
Creatinine clearance > 30 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study treatment
Recovered from all prior therapy
Prior systemic chemotherapy, immunotherapy, or biological therapy allowed
At least 14 days since prior radiotherapy or systemic therapy
At least 30 days since prior investigational agents
At least 14 days since other prior investigational drugs (for reasons other than the treatment of cancer)

Exclusion Criteria:

Untreated or symptomatic central nervous system (CNS) metastases
Concurrent serious systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
Uncontrolled diabetes
Myocardial infarction within the past 6 months
New York Heart Association (NYHA) class III or IV heart failure
Uncontrolled angina
Severe uncontrolled ventricular arrhythmias
Evidence of acute ischemia or active conduction system abnormalities by ECG
Peripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade > 2
Known hypersensitivity to bortezomib, boron, or mannitol
Serious medical or psychiatric illness likely to interfere with study participation
Prior bortezomib and/or cetuximab
Concurrent filgrastim (G-CSF) or other hematologic support during course 1 of study treatment